Amicus Therapeutics (NASDAQ:FOLD) Receives Overweight Rating from Cantor Fitzgerald

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report)'s stock had its "overweight" rating reissued by investment analysts at Cantor Fitzgerald in a research note issued on Wednesday,Benzinga reports. They presently have a $21.00 target price on the biopharmaceutical company's stock. Cantor Fitzgerald's price objective suggests a potential upside of 126.54% from the company's previous close.

A number of other research firms have also recently commented on FOLD. StockNews.com cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. raised their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, November 12th. Bank of America upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday, October 17th. Guggenheim raised their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research report on Monday. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, Amicus Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $16.88.

Amicus Therapeutics Trading Up 0.7 %

Shares of FOLD stock traded up $0.06 during trading hours on Wednesday, hitting $9.27. 2,504,613 shares of the company were exchanged, compared to its average volume of 2,618,857. The company has a 50 day simple moving average of $9.81 and a two-hundred day simple moving average of $10.54. The firm has a market cap of $2.77 billion, a P/E ratio of -27.26 and a beta of 0.62. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. Amicus Therapeutics has a fifty-two week low of $8.78 and a fifty-two week high of $14.03.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 22,901 shares of company stock valued at $259,863 over the last 90 days. Insiders own 2.20% of the company's stock.

Institutional Trading of Amicus Therapeutics

Several institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP increased its stake in Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock valued at $255,936,000 after buying an additional 2,856,101 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Amicus Therapeutics by 1,758.9% in the 2nd quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company's stock worth $18,790,000 after buying an additional 1,792,277 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Amicus Therapeutics in the third quarter valued at approximately $13,530,000. Assenagon Asset Management S.A. grew its holdings in shares of Amicus Therapeutics by 141.1% in the third quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company's stock valued at $21,765,000 after acquiring an additional 1,192,489 shares in the last quarter. Finally, Squarepoint Ops LLC increased its position in shares of Amicus Therapeutics by 159.1% during the second quarter. Squarepoint Ops LLC now owns 650,555 shares of the biopharmaceutical company's stock valued at $6,454,000 after acquiring an additional 399,449 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.